<DOC>
	<DOCNO>NCT00834184</DOCNO>
	<brief_summary>The purpose study determine nikkomycin Z safe administer different dose level 14 day . The study also determine blood level urinary excretion nikkomycin Z relation dose administer . Healthy patient eligible participate allocate receive nikkomycin Z ( various dos ) placebo .</brief_summary>
	<brief_title>Safety PK Nikkomycin Z Healthy Subjects</brief_title>
	<detailed_description>This protocol serve Phase I , randomize , double-blind , placebo control , multiple-dose study evaluate safety , tolerance pharmacokinetics nikkomycin Z. Nikkomycin Z previously study single dose protocol healthy male subject . This study design run parallel protocol VFCE-2007-001 provide additional data safety pharmacokinetics . The study involve total 32 subject ( 6 active/2 placebo per group ) multiple , rise dose strategy .</detailed_description>
	<mesh_term>Nikkomycin</mesh_term>
	<criteria>Age &gt; = 18 year &lt; = 40 year Male Female ( female , must negative pregnancy test agree use acceptable contraception method ) Able understand study give write informed consent Be determine healthy base medical laboratory evaluation Patients age 18 year 40 year Inability comprehend study provide write informed consent Inability comply study requirement History current evidence major organ disease include : Renal disease serum creatinine &gt; 1.5 mg/dL , significant hematuria proteinuria , know structural abnormality chronic kidney disease Hepatic disease active viral hepatitis , history hepatitis B hepatitis C , bilirubin &gt; 2.0 , ALT AST normal upper limit laboratory , alcoholic liver disease , chronic liver disease CNS disease cognitive dysfunction past history epilepsy , CNS infection , stroke , CNS bleed , severe headache , major psychiatric illness , current mental status change Lung disease history severe asthma , COPD , pulmonary tuberculosis , major lung disease Cardiac disease history current evidence ischemic coronary artery disease , myocardial infarction , heart failure , significant arrhythmia Gastrointestinal disease presence inflammatory bowel disease , difficulty swallowing , gastrointestinal problem would limit take oral medication may compromise absorption oral medication Cancer History hematologic malignancy solid tumor exclude basal cell carcinoma limit skin within past 5 year History autoimmune inflammatory disease rheumatoid arthritis lupus Any history evidence disease opinion physician would increase risk subject clinical trial participation Immunocompromised state solid organ transplant , cancer chemotherapy , BMT graft versus host disease , immunosuppressive therapy , HIV infection Recent weight loss great 10 % Regular use prescription medication , overthecounter medication , dietary/herbal supplement within 14 day day 1 . Occasional use acetaminophen overthecounter NSAID within 14 day window may allow P.I . 's discretion Subjects receive another investigational drug within 30 day enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>January 2010</verification_date>
	<keyword>nikkomycin Z</keyword>
	<keyword>evaluate safety , tolerance pharmacokinetics nikkomycin Z</keyword>
</DOC>